Announcements Trials
Browse Landscape

Phase

Phase 3 125Phase 2 99Phase 1 90Phase 1/2 78Phase 4 6Phase 2/3 4

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 23INDUSTRY 4NETWORK 3NIH 2OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2

Conditions

Multiple Myeloma 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Burkitt Lymphoma 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9anlotinib 7Trastuzumab 7Injections 7Rituximab 6atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5venetoclax 4Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Albumin-Bound Paclitaxel 4sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Dexamethasone × Clear all
NCT07095452 2026-05-27

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

AbbVie

Phase 2/3 Recruiting
660 enrolled
Plasma cell

Multiple Myeloma

NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07428369 2026-02-23

LINKER-MM8

Regeneron Pharmaceuticals

Phase 2/3 Not yet recruiting
1,570 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡